| Overview |
| bs-2438R-RBITC |
| AVEN Polyclonal Antibody, RBITC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Pig, Horse, Chicken, Rabbit |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human AVEN |
| 301-362/362 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 57099 |
| Cell membrane |
| 1700013A01Rik; 1700056A21Rik; mAven L; mAven S; MGC124011; Apoptosis caspase activation inhibitor; Cell death regulator Aven; OTTMUSP00000016129; PDCD12; Programmed cell death 12; RP23-52C15.2; AVEN_HUMAN |
| Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. AVEN is a recently discovered protein that blocks apoptosis induced by Apaf-1 and caspase-9. It is thought that AVEN functions by binding to Bcl-xL, an antiapoptotic member of the Bcl-2 family, and to Apaf-1, possibly interfering with the ability of Apaf-1 to self-associate, suggesting that AVEN impedes Apaf-1-mediated caspase activation. Higher levels of AVEN mRNA are seen in patients with acute leukemia than in control patients, suggesting that AVEN may be useful as a prognostic indicator in leukemia patients. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz